Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from CDTX

The biotech industry's expansion seems to stem from advancements in drug development, cutting-edge technology, and substantial government backing. Given these factors, prominent biotech stocks Surrozen (SRZN), Harmony Biosciences (HRMY), and Cidara Therapeutics (CDTX) could be solid watchlist additions now. Read on….

StockNews.com

3 Biotech Stocks Smart Money Is After

Biotech companies such as Biogen (BIIB), Cidara Therapeutics (CDTX), and Theratechnologies (THTX) with the interest of institutional investors could be worth investing in now. Continue reading….

StockNews.com

Are These Biotech Stocks a Buy or Sell for August: Bionano Genomics (BNGO) vs. Cidara Therapeutics (CDTX)?

Underpinned by undeniable growth trends of an aging population, breakthrough therapies, and the inelastic demand for healthcare products and medicines, the biotech industry is expected to perform well in the near term. Given this backdrop, let’s compare two biotech stocks, Bionano Genomics (BNGO) and Cidara Therapeutics (CDTX), to determine if…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Value Stocks With Great Returns

April’s robust labor market and persistently high inflation could strengthen the likelihood of interest rates remaining elevated for an extended period. So, fundamentally strong value stocks CIRCOR International (CIR), Consolidated Water (CWCO), and Cidara Therapeutics (CDTX), which have generated solid returns, could be one’s top picks now. Keep reading.

StockNews.com

4 Hyper-Growth Stocks That Could Soar

Coupled with the macroeconomic headwinds, the U.S. debt default crisis and consequent recessionary fears have triggered market volatility. Against this backdrop, quality growth stocks Boston Scientific (BSX), Cardinal Health (CAH), Cidara Therapeutics (CDTX), and Geospace Technologies (GEOS) could be solid buys now. Read on….

StockNews.com

4 Biotech Stocks You Don’t Want to Miss out on in 2023

The biotech industry is growing with considerable developments and government initiatives. Given the solid prospects of the industry, fundamentally sound biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Exelixis (EXEL), and Cidara Therapeutics (CDTX) could be excellent buys. Keep reading.

StockNews.com

3 Dirt-Cheap Stocks to Buy Right Now

Amid easing inflation numbers, the Fed is expected to slow down its rate hike aggression in 2023. Moreover, the stock market might witness a recovery this year. Given the favorable outlook, investors should consider buying dirt-cheap yet quality stocks Ambev (ABEV), VEON (VEON), and Cidara Therapeutics (CDTX) in 2023. Keep…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Stocks to Buy for Under $20 Right Now

The need for more advanced biotech research and development has increased amid an aging population and growing medical needs. Investors' sentiment toward biotech stocks has improved significantly over the past months. Given the industry's solid prospects, fundamentally sound biotech stocks Exelixis (EXEL), Innoviva (INVA), and Cidara Therapeutics (CDTX) might be…

StockNews.com

Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock

U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch.

Benzinga

Cidara Therapeutics's Return On Capital Employed Insights

According to Benzinga Pro data, during Q4, Cidara Therapeutics (NASDAQ:CDTX) posted sales of $7.22 million. Earnings were up 7.08%, but Cidara Therapeutics still reported an overall loss of $16.80 million.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals Incorporated

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.